Skip to main content

Table 2 Basic characteristics of included patients

From: Can low-dose intravenous immunoglobulin be an alternative to high-dose intravenous immunoglobulin in the treatment of children with newly diagnosed immune thrombocytopenia: a systematic review and meta-analysis

Study

Gender

F/M

Age

(years)

PC before treatment

(×109)

Dose of IVIg

(g/kg per day×days)

Type and dose of intravenous glucocorticoid

(mg/kg per day×days)

LD-IVIg

HD-IVIg

LD-IVIg

HD-IVIg

LD-IVIg

HD-IVIg

LD-IVIg

HD-IVIg

Bao H [26]

21/23

19/25

5.94 ± 1.26

6.04 ± 1.31

13.64 ± 5.26

14.15 ± 5.19

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

He WD [27]

25/23

22/26

5.22 ± 1.13

5.51 ± 1.02

< 20 (17 patients)

≥ 20 (31 patients)

< 20 (14 patients)

≥ 20 (34 patients)

0.2 × 5

0.4 × 5

DXMS (1.5 × 5)

Hou ZH [35]

25/33

27/31

5.3 ± 1.5

5.1 ± 1.3

19.97 ± 5.11

20.15 ± 5.16

0.2 × 5

0.4 × 5

DXMS (0.5 × 5)

Ji LJ [29]

22/24

23/23

3.80 ± 1.25

3.85 ± 1.20

20.10 ± 5.03

20.12 ± 4.88

0.2 × 5

0.4 × 5

DXMS (1.5 × 5)

Luo F [42]

44/46

10.23 ± 3.13

< 20

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

Su BX [44]

20/18

20/20

6.2 ± 1.1

5.8 ± 1.2

17.2 ± 6.1

16.4 ± 5.9

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

Qin HZ [38]

Not reported

5.6 ± 1.7

< 25

0.2 × 5

0.4 × 5

DXMS (1.5 × 5)

Yang YX [47]

15/19

16/17

5.96 ± 1.08

5.90 ± 1.01

13.90 ± 5.23

13.78 ± 5.18

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

Yu ZJ [48]

27/33

26/34

5.4 ± 1.6

5.6 ± 1.2

< 10 (52 patients)

10–25 (68 patients)

0.2 × 5

0.4 × 5

DXMS (0.5 × 5)

Zhu W [50]

31/34

29/36

6.14 ± 2.47

6.21 ± 2.83

< 10 (27 patients)

10–25 (38 patients)

< 10 (30 patients)

10–25 (35 patients)

0.2 × 5

0.4 × 5

DXMS (0.5 × 5)

Zhao SL [49]

6/11

9/8

8.1 ± 2.1

7.7 ± 1.9

14.9 ± 4.5

14.6 ± 4.9

0.2 × 5

0.4 × 5

DXMS (0.5 × 5)

Feng L [30]

38/30

2–15

3–77

0.2 × 5

0.4 × 5

MP (20 × 3)

He WH [34]

10/21

11/20

9 months-

9 years

9 months-

10 years

Not reported

0.2 × 5

0.4 × 5

DXMS (0.5 × 5)

Shi L [43]

15/17

16/16

6.41 ± 1.26

6.65 ± 1.33

20.02 ± 5.13

19.95 ± 4.98

0.2 × 5

0.4 × 5

DXMS (0.5 × 7)

Liang CJ [37]

Not reported

3 months-14 years

22.65 ± 15.7

28.21 ± 18.82

0.2 × 5

0.4 × 5

DXMS (0.5 × 5)

Tan YF [39]

Not reported

5.6 ± 1.8

14–57

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

Liu LK [40]

44/46

7.35 ± 1.21

Not reported

0.2 × 5

0.4 × 5

MP (20 × 4)

Yang B [46]

26/29

28/27

6.80 ± 1.28

6.23 ± 1.22

19.98 ± 5.06

20.15 ± 5.08

0.4 × 2

1.0 × 2

No

Wang Y [45]

9/10

8/11

6.66 ± 1.28

6.78 ± 1.12

18.12 ± 2.44

18.08 ± 2.65

0.3 × 2

0.4 × 5

DXMS (0.5 × 7)

Jin Y [36]

8/17

9/16

2.82 ± 2.17

2.46 ± 1.86

< 20 × 109/L

0.4 × 2

1.0 × 2

No

Yang Y [32]

30/21

22/29

3.9 ± 1.5

3.8 ± 1.3

Not reported

0.2 × 3

0.4 × 3

MP (20 × 4)

Hu XL [33]

12/38

11/39

4.21 ± 0.26

4.05 ± 0.12

Not reported

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

Gong CX [31]

18/12

18/15

2–16

3–16

1–19

0.2 × 5

0.4 × 5

No

Liu YY [41]

28/31

4.6(0.8-8.0)

6–21

1.0 × 1

0.4 × 5

DXMS (0.4 × 3)

Huang HY [28]

22/19

21/20

6.20 ± 2.46

6.24 ± 2.50

20.23 ± 5.26

20.14 ± 5.69

0.2 × 5

0.4 × 5

DXMS (1.0 × 5)

  1. Abbreviation F: female; M: male; PC: platelet count; DXMS: dexamethasone; MP: methylprednisolone